WESTMINSTER, Colo., USA, December 8, 2012 – Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, has been named a finalist in the Colorado BioScience Association (CBSA) “Rising  Star  of  the  Year” company award. The  company’s  innovative  products  are  used  in  the interventional radiology and interventional oncology markets.

“The Colorado BioScience Rising Star award is designated for an emerging company that has announced a major achievement during the year,” said April Giles, CBSA President and CEO. “We’re so very proud of our younger bioscience companies in the state and feel it’s particularly important to showcase those companies experiencing an outstanding year.”

Surefire Medical is among three companies that received the CBSA nomination.

“We are honored to be nominated by CBSA and are proud of our team’s achievements in innovation, growth and speed to market in 2012,” said Jim Chomas, President and CEO of  Surefire Medical.

About Colorado BioScience Association

The CBSA is a not-for-profit organization providing services and support for Colorado’s bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state’s biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.